SLC29A3
Basic information
Region (hg38): 10:71319259-71381423
Links
Phenotypes
GenCC
Source:
- H syndrome (Strong), mode of inheritance: AR
- dysosteosclerosis (Supportive), mode of inheritance: AR
- H syndrome (Supportive), mode of inheritance: AR
- H syndrome (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Histiocytosis-lymphadenopathy plus syndrome | AR | Allergy/Immunology/Infectious; Audiologic/Otolaryngologic; Dermatologic; Endocrine | Lipogranulomatous infiltration has been reported as benefiting from surgical interventions, radiotherapy, and medical treatment (eg, with cylophosphamide, prednisolone); Hormonal insufficiency, including hypogonadotropic hypogonadism, hypothyroidism, and growth hormone deficiency, may benefit from medical treatment; Individuals may manifest with early-onset hearing loss, and early recognition and treatment of hearing impairment may improve outcomes, including speech and language development | Allergy/Immunology/Infectious; Audiologic/Otolaryngologic; Cardiovascular; Dermatologic; Endocrine; Gastrointestinal; Musculoskeletal | 16118898; 16631937; 16650224; 16155931; 16155931; 18940313; 19336477; 19175903; 19889517; 20140240; 20199414; 20199539; 20399510; 20619369; 21178579; 21888995; 22238637; 22356918; 22653152; 22875837; 22989030; 23058913; 23406517; 23530176; 23623699 |
ClinVar
This is a list of variants' phenotypes submitted to
- H syndrome (24 variants)
- not provided (5 variants)
- SLC29A3-related disorder (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SLC29A3 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 109 | 122 | ||||
missense | 200 | 220 | ||||
nonsense | 7 | |||||
start loss | 0 | |||||
frameshift | 16 | 17 | ||||
inframe indel | 6 | |||||
splice donor/acceptor (+/-2bp) | 6 | |||||
splice region | 1 | 3 | 9 | 3 | 16 | |
non coding | 16 | 31 | 18 | 65 | ||
Total | 25 | 10 | 229 | 145 | 34 |
Highest pathogenic variant AF is 0.0000591
Variants in SLC29A3
This is a list of pathogenic ClinVar variants found in the SLC29A3 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
10-71319279-G-C | H syndrome | Uncertain significance (Jan 13, 2018) | ||
10-71319287-C-T | H syndrome | Uncertain significance (Jan 13, 2018) | ||
10-71319303-C-T | H syndrome | Benign (Jan 13, 2018) | ||
10-71319312-T-G | H syndrome | Likely pathogenic (Nov 08, 2022) | ||
10-71319318-C-T | H syndrome | Likely benign (Dec 11, 2023) | ||
10-71319324-G-C | H syndrome | Likely benign (Aug 30, 2023) | ||
10-71319390-G-A | not specified | Benign (Jan 24, 2024) | ||
10-71319472-T-C | Benign (Nov 12, 2018) | |||
10-71319545-C-G | Benign (Jun 19, 2021) | |||
10-71322739-C-T | H syndrome | Benign (Jan 21, 2024) | ||
10-71322744-T-C | H syndrome | Likely benign (May 18, 2021) | ||
10-71322750-C-T | H syndrome | Likely benign (Jun 18, 2021) | ||
10-71322752-A-G | H syndrome | Likely pathogenic (Oct 21, 2022) | ||
10-71322756-T-A | H syndrome | Likely pathogenic (Jun 10, 2023) | ||
10-71322759-C-T | H syndrome | Uncertain significance (Jul 06, 2022) | ||
10-71322760-C-T | H syndrome | Likely benign (Nov 18, 2023) | ||
10-71322761-G-A | H syndrome | Uncertain significance (Apr 12, 2022) | ||
10-71322764-G-A | H syndrome | Uncertain significance (Dec 11, 2020) | ||
10-71322772-G-A | H syndrome | Likely benign (Oct 11, 2023) | ||
10-71322775-C-A | H syndrome • Inborn genetic diseases | Uncertain significance (Jul 13, 2022) | ||
10-71322775-C-T | H syndrome | Likely benign (Jan 29, 2024) | ||
10-71322776-G-A | H syndrome • Inborn genetic diseases | Uncertain significance (Dec 19, 2023) | ||
10-71322785-C-G | H syndrome | Uncertain significance (Jun 22, 2021) | ||
10-71322794-A-G | H syndrome | Uncertain significance (Dec 11, 2023) | ||
10-71322805-CA-TG | H syndrome | Likely benign (Dec 26, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SLC29A3 | protein_coding | protein_coding | ENST00000373189 | 6 | 44128 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.29e-7 | 0.372 | 125694 | 1 | 53 | 125748 | 0.000215 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.477 | 292 | 270 | 1.08 | 0.0000173 | 3055 |
Missense in Polyphen | 103 | 90.015 | 1.1442 | 1056 | ||
Synonymous | -1.49 | 145 | 124 | 1.17 | 0.00000894 | 1046 |
Loss of Function | 0.652 | 12 | 14.7 | 0.816 | 7.28e-7 | 172 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000713 | 0.000713 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000110 | 0.000109 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000151 | 0.000149 |
Middle Eastern | 0.000110 | 0.000109 |
South Asian | 0.000523 | 0.000490 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). Mediates transport of adenine, adenosine and uridine, as well as several nucleoside analog drugs, such as anticancer and antiviral agents, including cladribine, cordycepin, tubercidin and AZT. Does not transport hypoxanthine. {ECO:0000269|PubMed:15701636}.;
- Pathway
- Purine metabolism;Transport of vitamins, nucleosides, and related molecules;SLC-mediated transmembrane transport;Transport of small molecules;Pyrimidine metabolism;Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane
(Consensus)
Recessive Scores
- pRec
- 0.135
Intolerance Scores
- loftool
- 0.595
- rvis_EVS
- 0.43
- rvis_percentile_EVS
- 77.29
Haploinsufficiency Scores
- pHI
- 0.260
- hipred
- N
- hipred_score
- 0.219
- ghis
- 0.431
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.468
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | High | High | High |
Primary Immunodeficiency | High | High | High |
Cancer | High | High | High |
Mouse Genome Informatics
- Gene name
- Slc29a3
- Phenotype
- cellular phenotype; neoplasm; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); immune system phenotype;
Gene ontology
- Biological process
- nucleoside transmembrane transport
- Cellular component
- lysosomal membrane;Golgi apparatus;integral component of membrane;late endosome membrane;intracellular membrane-bounded organelle
- Molecular function
- nucleoside transmembrane transporter activity;protein binding